Norgestrel is a lipid of Sterol Lipids (ST) class. Norgestrel is associated with abnormalities such as Acne, Deep Vein Thrombosis, Thromboembolism, Activated Protein C Resistance and Hydrometra. The involved functions are known as Thrombosis, Aquatic environment, Venous Thrombosis, Thrombus and Inspiration function. Norgestrel often locates in Glial. The associated genes with Norgestrel are Genes, Reporter. The related lipids are Estranes.
To understand associated biological information of Norgestrel, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Norgestrel is suspected in Thromboembolism, Acne, Deep Vein Thrombosis, Activated Protein C Resistance, Hydrometra, Withdrawal bleeding and other diseases in descending order of the highest number of associated sentences.
| Disease | Cross reference | Weighted score | Related literature |
|---|
We collected disease MeSH terms mapped to the references associated with Norgestrel
| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Gynecomastia | D006177 | 6 associated lipids |
| Venous Thrombosis | D020246 | 11 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
| Location | Cross reference | Weighted score | Related literatures |
|---|
| Function | Cross reference | Weighted score | Related literatures |
|---|
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
| Gene | Cross reference | Weighted score | Related literatures |
|---|
There are no associated biomedical information in the current reference collection.
| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Falcone F et al. | Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. | 2017 | J Gynecol Oncol | pmid:27670256 |
| Hasegawa S et al. | Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database. | 2017 | PLoS ONE | pmid:28732067 |
| Kiechle M and Neuenfeldt M | Experience with oral emergency contraception since the OTC switch in Germany. | 2017 | Arch. Gynecol. Obstet. | pmid:27896473 |
| Kim DH et al. | Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system. | 2017 | J Gynecol Oncol | pmid:27670255 |
| Festin MP et al. | Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies. | 2017 | Contraception | pmid:27527670 |
| Chang T et al. | Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement. | 2016 Jan-Feb | J Am Board Fam Med | pmid:26769874 |
| Phillips SJ et al. | Progestogen-only contraceptive use among breastfeeding women: a systematic review. | 2016 | Contraception | pmid:26410174 |
| Batur P et al. | Emergency contraception: A multispecialty survey of clinician knowledge and practices. | 2016 | Contraception | pmid:26363429 |
| Gungor T et al. | Clinicopathologic characteristics and treatment features of women with the incidental diagnosis of endometrial adenocarcinoma during infertility follow-up in Ankara, Turkey. | 2016 | Taiwan J Obstet Gynecol | pmid:27343306 |
| Apter D et al. | Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). | 2016 | Contraception | pmid:27153745 |
| Cano-Nicolau J et al. | Several synthetic progestins disrupt the glial cell specific-brain aromatase expression in developing zebra fish. | 2016 | Toxicol. Appl. Pharmacol. | pmid:27245768 |
| Ørbo A et al. | HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia. | 2016 | Br. J. Cancer | pmid:27537387 |
| Villegas G et al. | A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo. | 2016 | PLoS ONE | pmid:27428377 |
| Liegl S | Levonorgestrel-Releasing Intrauterine System vs. Oral Progestins for Treatment of Endometrial Hyperplasia. | 2016 | Am Fam Physician | pmid:27281840 |
| Phillips SJ et al. | The safety of Sino-implant (II) for women with medical conditions or other characteristics: a systematic review. | 2016 | Contraception | pmid:27217053 |
| Creinin MD et al. | Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. | 2016 | Contraception | pmid:27125892 |
| Sanghera S et al. | Pharmaceutical treatments to prevent recurrence of endometriosis following surgery: a model-based economic evaluation. | 2016 | BMJ Open | pmid:27084280 |
| Italia S and Brand H | Status of Emergency Contraceptives in Europe One Year after the European Medicines Agency's Recommendation to Switch Ulipristal Acetate to Non-Prescription Status. | 2016 | Public Health Genomics | pmid:27022731 |
| Quispe Calla NE et al. | Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. | 2016 | Mucosal Immunol | pmid:27007679 |
| Edelman AB et al. | Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. | 2016 | Contraception | pmid:27000996 |